Siddha Flower Essences Faces Nationwide Recall of 'temper tamer' Due to CGMP Deviations
Siddha Flower Essences, LLC. has initiated a Class II nationwide recall (D-0410-2025) for its 'temper tamer' Homeopathic Oral Spray due to Current Good Manufacturing Practice (CGMP) deviations. This event signals critical supply chain and regulatory risks for procurement directors and regulatory affairs heads, demanding immediate review of supplier compliance and potential sourcing alternatives to mitigate disruption.
FDA Mandates Nationwide Recall of Siddha Flower Essences' 'temper tamer' Over CGMP Failures
Siddha Flower Essences, LLC., based in Oxnard, CA, has initiated a Class II, firm-initiated recall (D-0410-2025) for its 'temper tamer' Homeopathic Oral Spray. This crucial regulatory action, commenced on April 28, 2025, stems directly from identified deviations from Current Good Manufacturing Practices (CGMP). The affected product, specifically Lot# S22-26424D with an expiration date of September 27, 2027, is distributed US Nationwide and carries the NDC 69779-020-01. For procurement directors, this recall signifies an immediate disruption in the supply of a specific homeopathic product, necessitating a swift assessment of inventory levels and potential impacts on retail channels. The Class II classification indicates that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. This classification underscores the importance of stringent quality controls in drug manufacturing, even for homeopathic formulations. Regulatory affairs heads must recognize that CGMP deviations, regardless of product classification, represent a fundamental failure in quality assurance systems. Such non-compliance can lead to product quality issues, safety concerns, and ultimately, market withdrawal, eroding consumer trust and incurring significant remediation costs. The ongoing status of this recall means that the firm's actions are still under FDA oversight, and further regulatory steps may be pending based on the adequacy of their corrective measures.
Operational Profile: Siddha Flower Essences' Oxnard Facility Under Scrutiny
The recall originates from Siddha Flower Essences, LLC.'s manufacturing facility located at 2350 Eastman Ave Ste 107, Oxnard, CA 93030-7265, within the United States. This facility is responsible for producing the 'temper tamer, 1 US fl oz. (29.6 mL), Homeopathic Oral Spray'. While specific details regarding the facility's production capacity, market share, or its role in global API supply are not available in the provided intelligence, the event highlights the critical importance of understanding a supplier's operational footprint. For supply chain VPs, the lack of granular data on a manufacturer involved in a nationwide recall underscores a potential blind spot in due diligence processes. It emphasizes the necessity for robust supplier qualification programs that extend beyond basic contractual agreements to include comprehensive site audits, quality system reviews, and a clear understanding of manufacturing capabilities and regulatory compliance history. Procurement teams should note that even smaller, specialized manufacturers of products like homeopathic remedies are subject to FDA CGMP regulations, and non-compliance at any scale can trigger significant market disruptions. The location in California, a major economic hub, means that any sustained operational issues could have broader implications for regional distribution networks handling similar health products.
Supply Chain Exposure: Assessing Impact on US Nationwide Distribution
The 'temper tamer' Homeopathic Oral Spray, subject to recall D-0410-2025, has a distribution pattern spanning US Nationwide. This broad reach means that numerous downstream partners, including wholesalers, distributors, pharmacies, and retailers, are directly exposed to the implications of this CGMP deviation. For business development executives and procurement directors, this necessitates an immediate and thorough review of inventory carrying the NDC 69779-020-01. The recall requires these entities to initiate procedures for product quarantine, return, or destruction, incurring direct logistical costs and potential financial losses from unsaleable inventory. Furthermore, the reputational risk extends beyond Siddha Flower Essences to any brand or retailer associated with the distribution of the affected product. Consumers, increasingly sensitive to product safety and quality, may view all homeopathic products or even specific retail channels with heightened skepticism. Supply chain VPs must ensure that their recall protocols are not only efficient but also transparent, providing clear communication to affected partners and consumers. This event serves as a stark reminder of the interconnectedness of the supply chain and the imperative for all stakeholders to have robust systems for tracking products, managing recalls, and verifying the ongoing compliance of their upstream suppliers to minimize commercial fallout.
Navigating Alternative Sourcing Amidst Regulatory Scrutiny for Homeopathic Products
With Siddha Flower Essences' 'temper tamer' Homeopathic Oral Spray under a nationwide Class II recall due to CGMP deviations, procurement teams face the immediate challenge of identifying and qualifying alternative suppliers. The provided intelligence does not name specific alternative manufacturers for this homeopathic product, highlighting a common challenge in specialized market segments. For procurement directors, the absence of readily available alternatives means a potentially extended timeline for securing new supply. The process involves comprehensive due diligence, including rigorous audits of potential new suppliers' quality management systems, manufacturing processes, and regulatory compliance history. This is particularly critical for homeopathic products, which, while regulated by the FDA, often operate within a distinct manufacturing framework. Qualification timelines for new suppliers can range from 6 to 18 months, depending on the complexity of the product and the stringency of internal quality requirements. Supply chain VPs should prioritize suppliers with a proven track record of FDA compliance and robust quality systems, potentially exploring manufacturers with diverse geographic footprints to mitigate future single-source risks. This incident underscores the strategic importance of maintaining a diversified supplier base and continuously evaluating the regulatory standing of all critical vendors, even those in niche markets, to safeguard against unforeseen disruptions and maintain market access.
Siddha Flower Essences' Regulatory Compliance History and Future Scrutiny
The current Class II recall (D-0410-2025) of 'temper tamer' Homeopathic Oral Spray due to CGMP deviations marks a significant regulatory event for Siddha Flower Essences, LLC. Based on available intelligence, there are no prior FDA Warning Letters, 483s, or Import Alerts specifically mentioned for this company. This suggests that the current recall may represent the firm's first major public regulatory action concerning manufacturing compliance. For regulatory affairs heads, this initial recall, while firm-initiated and voluntary, will undoubtedly place Siddha Flower Essences under heightened FDA scrutiny. The agency will closely monitor the firm's remediation efforts and the effectiveness of their Corrective and Preventive Actions (CAPA) plan. A failure to adequately address the underlying CGMP deviations could escalate into more severe enforcement actions, including the issuance of an FDA Warning Letter, which would publicly detail specific violations and demand prompt, comprehensive responses. Business development executives should be aware that a tarnished regulatory record can impact future market opportunities, partnership prospects, and investor confidence. This event serves as a critical inflection point for Siddha Flower Essences, requiring a robust and transparent commitment to quality system improvements to restore regulatory confidence and ensure long-term market viability.
Remediation Timeline and Commercial Repercussions for Siddha Flower Essences
As the recall of 'temper tamer' Homeopathic Oral Spray remains ongoing, Siddha Flower Essences, LLC. is now tasked with a comprehensive remediation effort to address the identified CGMP deviations. This includes not only the physical removal of the affected Lot# S22-26424D from the US Nationwide market but also a thorough investigation into the root causes of the manufacturing deficiencies. For regulatory affairs heads, the immediate priority is to develop and implement a robust Corrective and Preventive Action (CAPA) plan that satisfies FDA requirements. This plan must detail specific actions to correct the deviations, prevent recurrence, and verify the effectiveness of these measures. The FDA will closely monitor the firm's progress, and any perceived inadequacy in remediation could lead to further enforcement actions, such as an official Warning Letter or even an injunction, which would severely restrict or halt manufacturing operations. From a commercial standpoint, business development executives must contend with the immediate impact of lost sales from the recalled product and the potential for long-term brand erosion. Rebuilding consumer and distributor trust will require transparent communication and demonstrated commitment to quality. Supply chain VPs should anticipate potential delays in product reintroduction as the firm works to regain compliance, underscoring the need for proactive contingency planning and supplier diversification strategies to mitigate future supply chain vulnerabilities.